Evidence map›Paper›PMID 32360792›Full record

ReviewThe ocular surface2021

The potential of lipid mediator networks as ocular surface therapeutics and biomarkers.

Becca A Flitter, Xiaohui Fang, Michael A Matthay, Karsten Gronert

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The ocular surface, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Corneal deposits and nerve alterations in Bietti Corneoretinal Crystalline Dystrophy imaged using in vivo confocal microscopy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Observational
  10. Article
  11. Review
  12. Review
  13. Immune regulation of the ocular surface.Experimental eye research · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Becca A FlitterSchool of Optometry, University of California Berkeley, Berkeley, CA, 94720, USA; Vision Science Program, University of California Berkeley, Berkeley, CA, 94720, USA.
Xiaohui FangDepartment of Medicine and Anesthesia, University of California, San Francisco, CA, USA; Cardiovascular Research Institute, University of California, San Francisco, CA, USA.
Michael A MatthayDepartment of Medicine and Anesthesia, University of California, San Francisco, CA, USA; Cardiovascular Research Institute, University of California, San Francisco, CA, USA.
Karsten GronertSchool of Optometry, University of California Berkeley, Berkeley, CA, 94720, USA; Vision Science Program, University of California Berkeley, Berkeley, CA, 94720, USA; Infectious Diseases and Immunity Program, University of California Berkeley, Berkeley, CA, 94720, USA. Electronic address: kgronert@berkeley.edu.
University of California, Berkeley · USUniversity of California, San Francisco · US

Funding

NOVEL PARACRINE MECHANISMS FOR CELL-BASED THERAPY OF INJURED LUNGSR01HL134828 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI JI, HONG-LONG · 2017 to 2025
$3.4M
Protective Lipid Circuits in Corneal Injury and DiseaseR01EY016136 · NEI · UNIVERSITY OF CALIFORNIA BERKELEY · PI GRONERT, KARSTEN · 2005 to 2009
$1.9M
Regulatory Tissue Polymorphonuclear Leukocytes Determinants of Ocular Immune ResponsesR01EY026082 · NEI · UNIVERSITY OF CALIFORNIA BERKELEY · PI GRONERT, KARSTEN · 2016 to 2019
$1.5M
Sex-specific Regulation of Acute Inflammation and ResolutionR01EY022208 · NEI · UNIVERSITY OF CALIFORNIA BERKELEY · PI GRONERT, KARSTEN · 2012 to 2015
$1.5M
NEI NIH HHS R01 EY016136NEI NIH HHS R01 EY022208NEI NIH HHS R01 EY026082NHLBI NIH HHS R01 HL134828
6 · The paper itself

Abstract

In the last twenty years an impressive body of evidence in diverse inflammatory animal disease models and human tissues, has established polyunsaturated fatty acids (PUFA) derived specialized-pro-resolving mediators (SPM), as essential mediators for controlling acute inflammation, immune responses, wound healing and for resolving acute inflammation in many non-ocular tissues. SPM pathways and receptors are highly expressed in the ocular surface where they regulate wound healing, nerve regeneration, innate immunity and sex-specific regulation of auto-immune responses. Recent evidence indicates that in the eye these resident SPM networks are important for maintaining ocular surface health and immune homeostasis. Here, we will review and discuss evidence for SPMs and other PUFA-derived mediators as important endogenous regulators, biomarkers for ocular surface health and disease and their therapeutic potential.

Indexed as

InflammationInflammation MediatorsAnimalsBiomarkersFemaleHomeostasisHumansLipidsMaleBiomarkersInflammation MediatorsLipidsConjunctivaCorneaCorneal transplantDry eye diseaseInfectionNerve regenerationNeutrophilSpecialized pro-resolving mediatorsTearsWound healing

Identifiers

PMID32360792
PMCPMC7606340
OpenAlexW3021434016

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.